)
Sensus Healthcare (SRTS) investor relations material
Sensus Healthcare Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved exclusive CPT/CMS reimbursement codes for SRT and IG-SRT, providing reimbursement clarity and supporting broader adoption of non-invasive skin cancer treatments.
Entered 2026 with $22.1 million in cash, no debt, and a plan to expand the sales force.
Diversified customer base and international growth, reducing reliance on a single large customer.
Strategic focus on Fair Deal Agreement program, with active and pending FDA sites and significant year-over-year growth in treatments and patients.
Shipped 14 SRT systems in Q4 2025, up from six in Q3 (excluding largest customer); 70 systems shipped in 2025.
Financial highlights
Q4 2025 revenues were $4.9M, down from $31M in Q4 2024; full-year 2025 revenues were $27.5M, down from $41.8M in 2024.
Q4 gross profit was $1.9M (38.8% margin), down from $7.1M (54.2%) in Q4 2024; full-year gross profit was $11.9M (43.3% margin), down from $24.4M (58.4%) in 2024.
Q4 net loss was $3.2M, or -$0.19 per share, versus net income of $1.5M, or $0.09 per share, in Q4 2024; full-year net loss was $7.7M, or -$0.47 per share, versus net income of $6.6M, or $0.41 per share, in 2024.
Adjusted EBITDA for 2025 was -$9.6M, compared to $8.7M in 2024; Q4 adjusted EBITDA was -$3M (vs. $1.9M in Q4 2024).
Ended 2025 with $22.1M in cash and no outstanding borrowings; inventories increased to $14.6M from $10.1M.
Outlook and guidance
Q1 2026 system shipments expected to exceed Q4 2025 levels, even without contributions from the largest customer.
Full-year 2026 profitability targeted, with growth driven by new CPT/CMS codes, diversified customer base, and international expansion.
Guidance for 2026 excludes any contribution from the largest customer; any orders from them would be upside.
Plans to hire new sales representatives and leverage new reimbursement environment for growth.
- Q2 revenue rose 104% to $9.2M, with strong SRT sales and new recurring revenue model launched.SRTS
Q2 20242 Feb 2026 - Q3 revenue jumped 127% year-over-year, with future growth tied to major recurring agreements.SRTS
Q3 202414 Jan 2026 - Record revenue and shipments in 2024 set the stage for recurring growth via Fair Deal Agreements.SRTS
Q4 20242 Dec 2025 - Shareholders will vote on director election, incentive plan amendment, executive pay, and auditor ratification.SRTS
Proxy Filing1 Dec 2025 - Q1 2025 saw lower revenue and a net loss, but profitability is forecasted for the year.SRTS
Q1 202525 Nov 2025 - Q2 revenue and profit declined, but recurring revenue and FDA treatment volume increased.SRTS
Q2 202524 Nov 2025 - Q3 2025 revenue and profit fell, but new CMS codes and strong cash support future growth.SRTS
Q3 202515 Nov 2025 - SRT systems deliver high cure rates and strong financial growth in the expanding skin cancer market.SRTS
Investor Presentation24 Jun 2025
Next Sensus Healthcare earnings date
Next Sensus Healthcare earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)